Kardiovaskulaer farmakogenetik
Research output: Contribution to journal › Journal article › Research › peer-review
The past few years have witnessed considerable advances in the field of cardiovascular pharmacogenomics, not least as a result of genome-wide surveys. We here briefly review recent advances supporting the value of genetic information in the treatment of patients with betablockers, statins and warfarin. Although definitive proof that genotyping can change outcomes of patients with cardiovascular diseases await randomised trials, personalised cardiovascular pharmacotherapy is on the verge of entering clinical practice.
Udgivelsesdato: 2009-Apr
Udgivelsesdato: 2009-Apr
Translated title of the contribution | Cardiovascular pharmacogenomics |
---|---|
Original language | Danish |
Journal | Ugeskrift for læger |
Volume | 171 |
Issue number | 17 |
Pages (from-to) | 1405-7 |
Number of pages | 3 |
ISSN | 0041-5782 |
Publication status | Published - 2009 |
Bibliographical note
Keywords: Adrenergic beta-Antagonists; Anticholesteremic Agents; Anticoagulants; Cardiovascular Diseases; Cytochrome P-450 Enzyme System; Genetic Markers; Genotype; Humans; Pharmacogenetics; Treatment Outcome; Warfarin
ID: 20320160